Innate's Lung Cancer Drug Combo Doubles Key Response Metric

MARSEILLE, France – April 17, 2026 – A novel three-part drug combination has shown remarkable early success in treating early-stage lung cancer, potentially setting a new benchmark for a disease where recurrence remains a significant threat. Interim results from a Phase 2 study, announced today by French biotechnology firm Innate Pharma, show that its investigational drug, IPH5201, when added to a standard immunotherapy and chemotherapy regimen, more than doubled a key measure of treatment success prior to surgery.

The data, from the MATISSE clinical trial, are slated for a high-profile presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The results from an initial group of 40 patients with resectable non-small cell lung cancer (NSCLC) revealed a pathological complete response (pCR) rate—meaning the complete absence of viable cancer cells in tissue samples after treatment—that far exceeds current standards.

A Potential New Benchmark in Treatment

For patients with early-stage lung cancer that is eligible for surgery, the primary goal of pre-operative (neoadjuvant) therapy is to shrink or eliminate the tumor, making surgery more successful and reducing the risk of the cancer returning. The pCR rate is considered a critical early indicator of a treatment's long-term effectiveness.

The current standard of care, established by the landmark Phase 3 AEGEAN trial, combines the immunotherapy drug durvalumab with platinum-based chemotherapy. This regimen achieved a pCR rate of 17.2%.

In stark contrast, the interim data from the MATISSE trial paints a much more promising picture. For patients whose tumors expressed the biomarker PD-L1 at levels of 1% or higher, the addition of IPH5201 to durvalumab and chemotherapy resulted in a pCR rate of 35.7%. The effect was even more pronounced in a high-expression subgroup: patients with PD-L1 levels of 50% or greater achieved a pCR rate of 50%.

These figures represent a significant leap forward and suggest the new combination could offer a substantially more powerful tool for oncologists. Given these encouraging results, Innate Pharma has confirmed that the MATISSE study will continue to enroll patients with PD-L1-positive tumors to further validate these findings.

Unlocking the Immune System: The Science of Dual Inhibition

The impressive results hinge on a sophisticated strategy of attacking the cancer's defenses on two fronts. The tumor microenvironment is a complex battleground where cancer cells employ multiple tactics to hide from the body's immune system.

One well-known tactic involves the PD-1/PD-L1 pathway, which acts as a brake on immune cells. Drugs like durvalumab are designed to release this brake, allowing T-cells to recognize and attack cancer. However, this is often not enough.

Cancer cells also create a protective, immunosuppressive shield by manipulating the adenosine pathway. They use an enzyme called CD39 to convert a helpful, energy-carrying molecule called ATP—which can act as a "danger signal" to alert the immune system—into a highly immunosuppressive molecule called adenosine. This adenosine effectively puts nearby immune cells to sleep.

IPH5201, a first-in-class antibody, is designed to shut down this process by blocking the CD39 enzyme. This dual-action approach is intended to:
1. Reduce the production of immunosuppressive adenosine, clearing the "fog" that hides the tumor.
2. Increase the levels of immunostimulatory ATP, sending a louder "danger signal" to rally immune cells.

By combining IPH5201's ability to dismantle this adenosine shield with durvalumab's ability to release the T-cell brakes, the therapy aims to unleash a more comprehensive and powerful anti-tumor immune attack.

A Strategic Partnership and Crowded Field

Developing such a novel therapy is a massive undertaking, and IPH5201 is the product of a significant strategic collaboration between Innate Pharma and pharmaceutical giant AstraZeneca. The partnership, initiated in 2018, saw AstraZeneca take a nearly 10% equity stake in Innate and provide an upfront payment of $50 million for the option to co-develop IPH5201. The deal includes up to $885 million in potential milestone payments for Innate, demonstrating the high value placed on the drug's potential.

While this collaboration provides a powerful engine for development, IPH5201 is not the only player targeting this pathway. The therapeutic promise of blocking CD39 has attracted several other biotechnology companies, including Junshi Biosciences and Tizona Therapeutics, who have their own anti-CD39 candidates in earlier stages of clinical testing. The strong interim data from MATISSE, however, positions IPH5201 as a leading candidate in the field, particularly in the critical setting of resectable lung cancer.

The upcoming presentation at AACR will be delivered by Professor Fabrice Barlesi, CEO of the renowned Gustave Roussy cancer institute in France, lending further scientific weight to the findings.

The Path Forward for Patients

While the interim results are highly encouraging, the journey for IPH5201 is far from over. The MATISSE trial must be completed, and the results will need to be confirmed in a larger patient population, likely in a randomized Phase 3 trial. However, this early signal provides a strong rationale for pushing forward.

“Disrupting the adenosine pathway through CD39 inhibition with IPH5201, in combination with PD-1 blockade and chemotherapy, could enhance anti-tumor immune responses—particularly in patients with PD-L1 positive tumors, where we observed up to 50% pCR rate in the MATISSE trial,” commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma, in the company's statement. “This signal will be further investigated as we complete enrollment of the study in the PD-L1-positive population.”

For the hundreds of thousands of people diagnosed with operable lung cancer each year, the risk of recurrence after surgery casts a long shadow. The potential for a new neoadjuvant therapy that can dramatically increase the chances of eliminating the tumor before the first incision is made represents a profound new source of hope.